Yupelri (Revefenacin) for COPD

Overview
Yupelri is approved by the U.S. Food and Drug Administration (FDA) for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is prescribed to help manage symptoms of COPD on a daily basis and is not intended for use as a rescue treatment for sudden breathing problems. Yupelri is also known by its drug name, revefenacin.

Revefenacin belongs to a class of drugs called anticholinergics. It works by relaxing the muscles around the airways in the lungs, making it easier to breathe.

How do I take it?
Prescribing information states that Yupelri is taken as an inhalation solution using a standard jet nebulizer with a mouthpiece connected to an air compressor. The recommended dosage schedule is once daily. The medication should be taken exactly as prescribed by a health care provider.

Side effects
Common side effects of Yupelri include cough, nasopharyngitis (inflammation of the nose and throat), upper respiratory tract infection, headache, and back pain.

Rare but serious side effects may include paradoxical bronchospasm (worsening breathing difficulty), worsening of narrow-angle glaucoma (a type of eye pressure disorder), worsening of urinary retention, and immediate hypersensitivity reactions (severe allergic reactions). If any of these occur, contact a health care provider immediately.

For more information about this treatment, visit:
Yupelri (Revefenacin) Inhalation Solution, for Oral Inhalation — DailyMed

Revefenacin Oral Inhalation — MedlinePlus